Johannes Jungwirth

Dr. Johannes Jungwirth

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in Journal of Virology
Verified
Journal Article
Open access
Stefanie Deinhardt-EmmerStefanie Deinhardt-Emmer
Stefanie Deinhardt-Emmer
SBSarah Böttcher
Sarah Böttcher
CHClio Häring
Clio Häring
LGLiane Giebeler
Liane Giebeler
AHAndreas Henke
Andreas Henke
CEChristina Ehrhardt
Christina Ehrhardt
SARS-CoV-2 challenges health care systems and societies worldwide in unprecedented ways. Although numerous new studies have been conducted, research to better understand the molecular pathogen-host interactions are urgently needed.

Verified
Journal Article
Open access
PDF file
CHClio Häring
Clio Häring
JJJohannes Jungwirth
Johannes Jungwirth
JSJosefine Schroeder
Josefine Schroeder
BLBettina Löffler
Bettina Löffler
BEBeatrice Engert
Beatrice Engert
CEChristina Ehrhardt
Christina Ehrhardt
As vaccination efforts against SARS-CoV-2 progress in many countries, there is still an urgent need for efficient antiviral treatment strategies for those with severer disease courses, and lately, considerable efforts have been undertaken to repurpose existing drugs as antivirals. The local anaesthetic procaine has been investigated for antiviral properties against several viruses over the past decades. Here, we present data on the inhibitory effect of the procaine prodrugs ProcCluster® and procaine hydrochloride on SARS-CoV-2 infection in vitro. Both procaine prodrugs limit SARS-CoV-2 progeny virus titres as well as reduce interferon and cytokine responses in a proportional manner to the virus load. The addition of procaine during the early stages of the SARS-CoV-2 replication cycle in a cell culture first limits the production of subgenomic RNA transcripts, and later affects the replication of the viral genomic RNA. Interestingly, procaine additionally exerts a prominent effect on SARS-CoV-2 progeny virus release when added late during the replication cycle, when viral RNA production and protein production are already largely completed.

13 January 2025 in Life Sciences
Verified
Journal Article
Open access
JJJohannes Jungwirth
Johannes Jungwirth
AMAndreas O. Mieland
Andreas O. Mieland
APAndrea Piée-Staffa
Andrea Piée-Staffa
THTino Heimburg
Tino Heimburg
WBWalburgis Brenner
Walburgis Brenner
Oliver KrämerOliver Krämer
Oliver Krämer
The protein deacetylase HDAC6 has been controversially linked to cancer cell proliferation and viral propagation. We analyzed whether a pharmacological depletion of HDAC6 with a recent proteolysis-targeting chimera (PROTAC) kills tumor cells. We show that low micromolar doses of the cereblon-based PROTAC TH170, but not its inactive analog TH170E, induce proteasomal degradation of HDAC6. The elimination of HDAC6 by TH170 does not compromise leukemia cell growth and survival, DNA integrity, and the stability of selected cancer-relevant proteins. Increasing the doses of TH170 generates a hook-effect on HDAC6 degradation and the apoptosis-associated fragmentation of HDAC6. Unlike the specific elimination of HDAC6 that low doses of TH170 evoke, this fragmentation of HDAC6 is linked to apoptosis and an accumulation of acetylated histones. Thus, like HDAC6 inhibitors, pharmacological degraders of HDAC6 do not induce leukemic cell death unless they are used in non-selective concentrations. Bioinformatic analyses of 91 lymphoid, 37 myeloid, and 125 lung cancer cells in which HDAC6 was deleted by CRISPR-Cas9 corroborate these data. HDAC6 is expressed in various bronchus and lung cell types. In a human lung cell model, TH170 reduces influenza A virus replication dependent on the strain and without compromising cell vitality. These data suggest that pharmacologically amenable kinase-independent functions of HDAC6 control viral replication. Eliminating HDAC6 could be a promising anti-viral strategy with a benign impact on host cells.

14 August 2024 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CHClio Häring
Clio Häring
JSJosefine Schroeder
Josefine Schroeder
JJJohannes Jungwirth
Johannes Jungwirth
BLBettina Löffler
Bettina Löffler
AHAndreas Henke
Andreas Henke
CEChristina Ehrhardt
Christina Ehrhardt
Introduction: Treatment of influenza A virus infections is currently limited to few direct acting antiviral substances. Repurposing other established pharmaceuticals as antivirals could aid in improving treatment options.Methods: This study investigates the antiviral properties of ProcCluster® and procaine hydrochloride, two derivatives of the local anesthetic procaine, in influenza A virus infection of A549, Calu-3 and MDCK cells.Results: Both substances inhibit replication in all three of these cell lines in multi-cycle experiments. However, cell line-dependent differences in the effects of the substances on viral RNA replication and subsequent protein synthesis, as well as release of progeny viruses in single-cycle experiments can be observed. Both ProcCluster® and procaine hydrochloride delay endosome fusion of the virus early in the replication cycle, possibly due to the alkaline nature of the active component procaine. In A549 and Calu-3 cells an additional effect of the substances can be observed at late stages in the first replication cycle. Interestingly, this effect is absent in MDCK cells. We demonstrate that ProcCluster® and procaine hydrochloride inhibit phospholipase A2 (PLA2) enzymes from A549 but not MDCK cells and confirm that specific inhibition of calcium independent PLA2 but not cytosolic PLA2 has antiviral effects.Discussion: We show that ProcCluster® and procaine hydrochloride inhibit influenza A virus infection at several stages of the replication cycle and have potential as antiviral substances.

Verified
Journal Article
Open access
PDF file
SCSandra Classen
Sandra Classen
ERElena Rahlf
Elena Rahlf
JJJohannes Jungwirth
Johannes Jungwirth
NANina Albers
Nina Albers
LHLuca Philipp Hebestreit
Luca Philipp Hebestreit
Kerstin BorgmannKerstin Borgmann
Kerstin Borgmann
BRCA1 is a well-known breast cancer risk gene, involved in DNA damage repair via homologous recombination (HR) and replication fork protection. Therapy resistance was linked to loss and amplification of the BRCA1 gene causing inferior survival of breast cancer patients. Most studies have focused on the analysis of complete loss or mutations in functional domains of BRCA1. How mutations in non-functional domains contribute to resistance mechanisms remains elusive and was the focus of this study. Therefore, clones of the breast cancer cell line MCF7 with indels in BRCA1 exon 9 and 14 were generated using CRISPR/Cas9. Clones with successful introduced BRCA1 mutations were evaluated regarding their capacity to perform HR, how they handle DNA replication stress (RS), and the consequences on the sensitivity to MMC, PARP1 inhibition, and ionizing radiation. Unexpectedly, BRCA1 mutations resulted in both increased sensitivity and resistance to exogenous DNA damage, despite a reduction of HR capacity in all clones. Resistance was associated with improved DNA double-strand break repair and reduction in replication stress (RS). Lower RS was accompanied by increased activation and interaction of proteins essential for the S phase-specific DNA damage response consisting of HR proteins, FANCD2, and CHK1.

20 October 2019 in Human Molecular Genetics
Verified
Journal Article
Open access
MBMuthiah Bose
Muthiah Bose
JSJuliane Sachsenweger
Juliane Sachsenweger
NLNiina Laurila
Niina Laurila
APAnn Christin Parplys
Ann Christin Parplys
JWJonas Willmann
Jonas Willmann
HPHelmut Pospiech
Helmut Pospiech
Whilst heterozygous germline mutations in the ABRAXAS1 gene have been associated with a hereditary predisposition to breast cancer, their effect on promoting tumourigenesis at the cellular level has not been explored. Here, we demonstrate in patient-derived cells that the Finnish ABRAXAS1 founder mutation (c.1082G>A, Arg361Gln), even in the heterozygous state leads to decreased BRCA1 protein levels as well as reduced nuclear localization and foci formation of BRCA1 and CtIP. This causes disturbances in basal BRCA1-A complex localization, which is reflected by a restraint in error-prone DNA double-strand break (DSB) repair pathway usage, attenuated DNA damage response and deregulated G2-M checkpoint control. The current study clearly demonstrates how the Finnish ABRAXAS1 founder mutation acts in a dominant-negative manner on BRCA1 to promote genome destabilisation in heterozygous carrier cells.